Premium Nahrungsergänzungsmittel | artgerecht

Juvenile Idiopathic Arthritis (JIA) - Definition

Juvenile idiopathic arthritis (JIA) is the most common chronic joint disease in children and adolescents. It causes joint inflammation and can impair mobility over time.

Regular tips about health Regular tips about health

Things worth knowing about "Juvenile idiopathic arthritis"

Juvenile idiopathic arthritis (JIA) is the most common chronic joint disease in children and adolescents. It causes joint inflammation and can impair mobility over time.

What is juvenile idiopathic arthritis?

Juvenile idiopathic arthritis (JIA) is a chronic inflammatory joint disease that begins in children and adolescents under the age of 16 and lasts for at least 6 weeks. The term “idiopathic” means that no specific cause has been identified. JIA is not a single disease but rather an umbrella term for several subtypes that differ in their course, severity, and the joints involved.

Causes and risk factors

The exact cause of JIA remains unclear. It is believed that a dysregulation of the immune system plays a central role, in which the immune system mistakenly attacks the body's own joint tissue. The following factors are discussed:

Genetic predisposition: Certain genetic markers (e.g., HLA genes) increase the risk of developing JIA.
Environmental triggers: Infections or other external factors may trigger the disease in genetically susceptible children.
Immunological dysregulation: Overactivation of immune cells leads to chronic inflammatory reactions in the joints.

Subtypes of JIA

The International League of Associations for Rheumatology (ILAR) distinguishes several subtypes:

Oligoarticular JIA: Affects up to 4 joints; most common form; increased risk of eye inflammation (uveitis).
Polyarticular JIA: Affects 5 or more joints; can be rheumatoid factor (RF)-positive or RF-negative.
Systemic JIA: Involves joints as well as internal organs; characteristic features include high fever and a distinctive skin rash.
Enthesitis-related arthritis: Inflammation at tendon insertion sites; more common in older boys.
Psoriatic arthritis: Combination of joint involvement and psoriasis.
Undifferentiated arthritis: Does not fulfill criteria for any single subtype or meets criteria for more than one.

Symptoms

Symptoms of JIA can vary depending on the subtype. Common complaints include:

Joint pain and swelling, often most pronounced in the morning (morning stiffness)
Redness and warmth over affected joints
Limited range of motion and loss of function
Fatigue and general malaise
In systemic JIA: high fever, skin rash, enlarged lymph nodes and organ involvement
Eye inflammation (uveitis), often without symptoms, particularly in the oligoarticular form

Diagnosis

The diagnosis of JIA is based on clinical criteria, as no single definitive blood test exists. The diagnostic process includes:

Medical history and physical examination: Assessment of affected joints, duration of symptoms, and accompanying signs.
Laboratory tests: Inflammatory markers (CRP, ESR), complete blood count, rheumatoid factor (RF), antinuclear antibodies (ANA), HLA-B27.
Imaging: Ultrasound and MRI to evaluate joint inflammation and cartilage damage.
Eye examination: Regular slit-lamp examinations to rule out uveitis.

Treatment

The goal of treatment is to control inflammation, preserve joint function, and improve quality of life. Therapy is individually tailored:

Pharmacological treatment

Nonsteroidal anti-inflammatory drugs (NSAIDs): Ibuprofen or naproxen for pain relief and reduction of inflammation.
Corticosteroids: Used for severe flares, either short-term or as intra-articular injections.
Disease-modifying antirheumatic drugs (DMARDs): Methotrexate is the most commonly used DMARD in JIA.
Biologics: For example, TNF inhibitors (etanercept, adalimumab) or IL-6 inhibitors (tocilizumab) for treatment-resistant cases.

Non-pharmacological treatment

Physiotherapy: To maintain joint mobility and muscle strength.
Occupational therapy: Support with daily activities and assistive devices.
Psychosocial support: Assistance for the child and family in coping with chronic illness.

Prognosis and long-term outlook

The course of JIA varies considerably. Some children achieve lasting remission, while others require long-term treatment. With early diagnosis and consistent therapy, the majority of affected children can lead largely normal lives. Regular follow-up examinations, particularly of the eyes, are essential.

References

Petty RE et al. - International League of Associations for Rheumatology Classification of Juvenile Idiopathic Arthritis, Journal of Rheumatology, 2004.
Ravelli A, Martini A - Juvenile idiopathic arthritis, The Lancet, 2007.
World Health Organization (WHO) - Chronic diseases and health promotion, www.who.int.

Building Blocks for a Healthy Life

As an integrated manufacturer, we develop & produce evidence-based, patented, and non-patented formulations. We work exclusively with plant and natural extracts according to the strictest purity & quality standards.
The combination of science & modern technology with the laws of nature creates solutions consistently tailored to humans – for the highest good: health.